A drug first developed at Ohio University to block the growth‑hormone receptor made tough‑to‑treat lung cancer cells much more vulnerable to standard chemotherapy in lab experiments, researchers report. In tests on human and mouse non‑small‑cell lung cancer cells, the growth‑hormone‑receptor blocker pegvisomant, sold as Somavert, boosted chemo‑induced cell death and cut the dose of cisplatin and doxorubicin needed to knock back tumors. The work points to a possible new use for an FDA‑approved medicine, but the team is clear that everything so far is preclinical and strictly in the lab.
GHR levels tied to shorter survival in patient data
The researchers dug into tumor datasets, including The Cancer Genome Atlas, and found a stark pattern. Patients whose tumors showed high levels of the growth‑hormone receptor (GHR) lived about 36 to 40 months, compared with roughly 66 months for those with low‑GHR tumors, according to the International Journal of Molecular Sciences. The study reports that high GHR expression tracks with increased activity of ABC drug‑efflux transporters and activation of epithelial‑to‑mesenchymal transition programs that are linked to chemotherapy resistance. Taken together, that biology offers a clear rationale for testing whether blocking growth‑hormone signaling can restore tumors’ sensitivity to chemo.
Pegvisomant restores chemo sensitivity in lab tests
In cell‑based assays, the team treated chemotherapy‑resistant lung cancer lines with pegvisomant plus standard drugs and saw more cell death and fewer signs of invasive behavior, according to Ohio University. “By blocking the growth hormone receptor, we may be able to improve the effectiveness of existing treatments,” Kopchick said in a statement to the university. It is a simple idea on paper: switch off the receptor and make the old standbys hit harder.
Drug cut chemo doses and tamed drug‑pump proteins
The published paper notes that adding pegvisomant to cisplatin or doxorubicin lowered the drugs’ IC50 values in several lung cancer cell lines, in some cases by several fold, and also dampened the ABC transporters that normally pump chemotherapy agents out of tumor cells, according to the International Journal of Molecular Sciences. Cleveland.com carried a summary of the work and the team’s comments. The scientists stress that making cancer cells more sensitive in a dish does not automatically translate into better outcomes for real patients without supportive animal studies and clinical trials.
Next steps: mice, safety checks and trials
Ohio University says the group will move next to testing lung cancer cells in mice and expanding animal work that could eventually support clinical studies if the results hold up. Both the university’s news release and the journal article underscore that careful safety and dosing work, followed by rigorously designed human trials, must come before oncologists even think about using pegvisomant off‑label for lung cancer. For now, this is an intriguing lab result, not a new standard of care.
About pegvisomant and practical limits
Pegvisomant grew out of work led by Kopchick and collaborators and has been profiled extensively in the scientific literature; a review of its discovery and mechanism appears on PubMed. Marketed as Somavert, it already has FDA approval for treating acromegaly and comes with monitoring requirements, including liver‑function tests and glucose checks, as detailed in the FDA label. That regulatory track record makes pegvisomant an appealing repurposing candidate, but any move into oncology would still require close attention to dose, drug interactions and long‑term safety.
National and local outlets have picked up the story; Cleveland.com offers a lay summary along with comments from the researchers. For patients and families watching from the sidelines, the takeaway is cautious optimism. The strategy works in the lab, now it has to prove itself in animals and, if it makes it that far, in carefully controlled human trials before anyone can say whether it truly improves lung cancer outcomes.
